Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ.

PURPOSE While the mortality associated with ductal carcinoma in situ (DCIS) is minimal, the risk of ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) is relatively high. Radiation therapy (RT) and antiestrogen agents reduce the risk of IBTR and are considered standard treatment options after BCS. However, they have never been proven to improve survival, and in themselves carry rare but serious risks. Individualized estimation of IBTR risk would assist in decision making regarding the various treatment options for women with DCIS. PATIENTS AND METHODS From 1991 to 2006, 1,868 consecutive patients treated with BCS for DCIS were identified. A multivariate Cox proportional hazards model was constructed using the 1,681 in whom data were complete. Ten clinical, pathologic, and treatment variables were built into a nomogram estimating probability of IBTR at 5 and 10 years after BCS. The model was validated for discrimination and calibration using bootstrap resampling. RESULTS The DCIS nomogram for prediction of 5- and 10-year IBTR probabilities demonstrated good calibration and discrimination, with a concordance index of 0.704 (bootstrap corrected, 0.688) and a concordance probability estimate of 0.686. Factors with the greatest influence on risk of IBTR in the model included adjuvant RT or endocrine therapy, age, margin status, number of excisions, and treatment time period. CONCLUSION The DCIS nomogram integrates 10 clinicopathologic variables to provide an individualized risk estimate of IBTR in a woman with DCIS treated with BCS. This tool may assist in individual decision making regarding various treatment options and help avoid over- and undertreatment of noninvasive breast cancer.

[1]  J. Peterse,et al.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[3]  M. Kattan,et al.  Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram , 2005, Annals of Surgical Oncology.

[4]  E. Rakovitch,et al.  Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[6]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[7]  M. Silverstein,et al.  Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? , 2007, Journal of surgical oncology.

[8]  L. Liberman,et al.  Long term follow‐up of women with ductal carcinoma in situ treated with breast‐conserving surgery , 1999, Cancer.

[9]  J. Niland,et al.  Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Soran,et al.  Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. , 2009, Journal of the American College of Surgeons.

[11]  L. Holmberg,et al.  Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Jagsi,et al.  The management of ductal carcinoma in situ in North America and Europe , 2004, Cancer.

[13]  E. Darai,et al.  Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. , 2009, Journal of Clinical Oncology.

[14]  Michael W Kattan,et al.  Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Thiery,et al.  Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.

[16]  B Fisher,et al.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. , 1993, The New England journal of medicine.

[17]  K. Kerlikowske,et al.  Detection of ductal carcinoma in situ in women undergoing screening mammography. , 2002, Journal of the National Cancer Institute.

[18]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[19]  Mithat Gonen,et al.  Individualized prediction of colon cancer recurrence using a nomogram. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Giles,et al.  CHANGES IN THE MANAGEMENT OF DUCTAL CARCINOMA IN SITU BEFORE THE RELEASE OF CLINICAL PRACTICE RECOMMENDATIONS IN AUSTRALIA: THE CASE IN VICTORIA , 2006, ANZ journal of surgery.

[21]  M. Silverstein The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. , 2003, American journal of surgery.

[22]  Kay Nieselt,et al.  Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. , 2006, Cancer research.

[23]  H. Macdonald,et al.  Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast. , 2006, American journal of surgery.

[24]  Murray F. Brennan,et al.  Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the Pancreas , 2004, Annals of surgery.

[25]  K. Polyak Is Breast Tumor Progression Really Linear? , 2008, Clinical Cancer Research.

[26]  Molin Wang,et al.  Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Harrell,et al.  USING FULL PROBABILITY MODELS TO COMPUTE PROBABILITIES OF ACTUAL INTEREST TO DECISION MAKERS , 2001, International Journal of Technology Assessment in Health Care.

[28]  D. Wazer,et al.  An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ , 2007, Cancer.

[29]  Robert C. Frazier,et al.  Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Bevilacqua,et al.  Predictive Probability of Four Different Breast Cancer Nomograms for Nonsentinel Axillary Lymph Node Metastasis in Positive Sentinel Node Biopsy , 2009 .

[31]  T. Buchholz,et al.  Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? , 2007, Journal of surgical oncology.

[32]  S. Martino,et al.  Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Macdonald,et al.  Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. , 2006, American journal of surgery.

[34]  M. Kattan,et al.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Gonen,et al.  Concordance probability and discriminatory power in proportional hazards regression , 2005 .

[36]  Barbara L. Smith,et al.  Prospective study of wide excision alone for ductal carcinoma in situ of the breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L. Solin Is excision alone adequate treatment for low-risk ductal carcinoma-in-situ of the breast? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Raj,et al.  How to build and interpret a nomogram for cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J Costantino,et al.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17 , 1999, Cancer.

[40]  S. Martino,et al.  The influence of margin width on local control of ductal carcinoma in situ of the breast. , 1999, The New England journal of medicine.

[41]  L. Holmberg,et al.  SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening , 2006, Acta oncologica.

[42]  M. Kattan,et al.  Evidence for the usefulness of nomograms , 2007, Nature Clinical Practice Urology.

[43]  M. Ernst,et al.  Validation of a Nomogram to Predict the Risk of Nonsentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node Biopsy: Validation of the MSKCC Breast Nomogram , 2009, Annals of Surgical Oncology.

[44]  Charles M. Perou,et al.  Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.

[45]  Michael W Kattan,et al.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Costantino,et al.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Hiram S. Cody,et al.  A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy , 2003, Annals of Surgical Oncology.

[48]  Beth A Virnig,et al.  Trends in the Treatment of Ductal Carcinoma In Situ of the Breast , 2004 .

[49]  M. Silverstein,et al.  Duct carcinoma in situ: 227 cases without microinvasion. , 1992, European journal of cancer.

[50]  L. Holmberg,et al.  Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. , 2007, European journal of cancer.

[51]  M. Silverstein,et al.  A prognostic index for ductal carcinoma in situ of the breast , 1996, Cancer.

[52]  J. Houghton Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial , 2003, The Lancet.

[53]  I. Henderson,et al.  Overdiagnosis and overtreatment of breast cancer: Rates of ductal carcinoma in situ: a US perspective , 2005, Breast Cancer Research.

[54]  J. Coindre,et al.  Application of the Van Nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examinated by serial macroscopic sectioning: Practical considerations , 2000, Breast Cancer Research and Treatment.

[55]  N. Wolmark,et al.  Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. , 2001, Seminars in oncology.

[56]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[57]  N. Bundred,et al.  Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast‐conserving surgery , 2003, The British journal of surgery.

[58]  Anthony J. Guidi,et al.  Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: Possible importance of family history. , 1995, The cancer journal from Scientific American.

[59]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[60]  Robert Gray,et al.  Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Kattan,et al.  Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  E. Brogi,et al.  The Influence of Margin Width and Volume of Disease Near Margin on Benefit of Radiation Therapy for Women With DCIS Treated With Breast-Conserving Therapy , 2010, Annals of surgery.

[63]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[64]  E. Brogi,et al.  Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast‐conserving therapy , 2009, Cancer.

[65]  J. Peterse,et al.  Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853 , 2000, The Lancet.

[66]  M. Silverstein,et al.  Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. , 2004, American journal of surgery.

[67]  D. Schultz,et al.  Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Costantino,et al.  Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. , 2007, American journal of clinical pathology.

[69]  S. Lakhani,et al.  In situ carcinoma - can we predict which patient will come back with a recurrence? , 2007, Cancer cell.